A Case of Opioid Toxicity on Conversion From Extended-Release Oxycodone and Naloxone to Extended-Release Oxycodone in a Patient With Liver Dysfunction-Reference-Cited by-同舟云学术

A Case of Opioid Toxicity on Conversion From Extended-Release Oxycodone and Naloxone to Extended-Release Oxycodone in a Patient With Liver Dysfunction

Published:2017-02 Issue:2 Volume:53 Page:e1-e2
ISSN:0885-3924
Container-title:Journal of Pain and Symptom Management
language:en
Short-container-title:Journal of Pain and Symptom Management

Author:

Franklin Abigail E.,Lovell Melanie R.,Boyle Frances

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Neurology (clinical),General Nursing

Reference10 articles.

1. Long term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain;Ahmedzai;Support Care Cancer,2015

2. Low absolute bioavailability of oral naloxone in healthy subjects;Smith;Int J Clin Pharmacol Ther,2012

3. A cautionary tale of oral naloxone;Burns;J Pain Symptom Manage,2014

4. Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis;Kang;J Pain Symptom Manage,2013

5. Australian Medicines Handbook. Available at: https://amhonline.amh.net.au.acs.hcn.com.au/chapters/chap-03/drugs-pain-relief/analgesics-opioid/oxycodone#oxycodone.08, Accessed July 25, 2016.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opioid toxicity after oxycodone/naloxone to oxycodone conversion: case series;BMJ Supportive & Palliative Care;2024-02-26

2. Analgetika;Arzneimitteltherapie in der Palliativmedizin;2022

3. Oxycodone/naloxone prolonged‐release tablets in patients with moderate‐to‐severe, chronic cancer pain: Challenges in the context of hepatic impairment;Asia-Pacific Journal of Clinical Oncology;2021-03-03

4. Pharmacovigilance in Hospice/Palliative Care: De-Prescribing Combination Controlled Release Oxycodone-Naloxone;Journal of Palliative Medicine;2020-05-01

5. Adverse effects of modified release oxycodone/naloxone in patients with moderate to severe liver impairment;Medical Journal of Australia;2018-09